Peptides for Women: A Hormonal-Health Overview

Peptides for women are short amino-acid chains studied as signaling molecules across sexual, metabolic, and bone health. Only one — bremelanotide (PT-141), sold as Vyleesi — is FDA-approved, for hypoactive sexual desire disorder in premenopausal women. Most others are research compounds with limited human data. This guide covers the evidence, sex-specific considerations, safety, and 2026 legal status.

Peptides for women at a glance

• What they are: short chains of amino acids studied as hormone-axis and tissue-signaling molecules
• The one FDA-approved option: bremelanotide (PT-141 / Vyleesi), 1.75 mg subcutaneous, as-needed, for acquired generalized HSDD in premenopausal women
• Commonly discussed (not approved): GH-axis peptides such as CJC-1295 and ipamorelin; tesamorelin (approved only for HIV-associated lipodystrophy); BPC-157
• Evidence level: strong for PT-141 in its narrow indication; preliminary-to-preclinical for most others in women
• Key sex-specific factor: estrogen status alters growth-hormone response and drug clearance
• 2026 FDA status: 12 peptides removed from the Category 2 "do not compound" list in April 2026; a PCAC review of seven peptides is scheduled for July 23–24, 2026

What are peptides, and why do they matter for women's hormonal health?

Peptides are short chains of amino acids — typically fewer than 50 — that act as biological messengers. Hormones such as insulin, oxytocin, and growth-hormone-releasing hormone (GHRH) are themselves peptides, so a synthetic peptide can, in principle, nudge a specific hormonal pathway rather than flooding the body with a hormone directly.

That targeted action is why peptides are discussed in the context of women's health, where the endocrine system shifts dramatically across the menstrual cycle, perimenopause, and postmenopause. The relevant point for any woman evaluating peptides is that female physiology is governed by a fluctuating interplay of estrogen, progesterone, FSH, and LH. In the best-studied example, the growth-hormone axis, estrogen status measurably alters hormone output: estrogen regulates the GH–IGF-1 axis both in how much GH is secreted and in the pattern of its release (Veldhuis, 1998, Growth Horm IGF Res), and exogenous estrogen further modulates GH and IGF-1 production across the lifespan (Southmayd & De Souza, 2017, Growth Horm IGF Res). Despite this, most peptides have not been tested specifically in female or perimenopausal populations — a meaningful evidence gap discussed throughout this overview.

For foundational context, see our overview of what peptides are.

Which peptide is actually FDA-approved for women?

One peptide is FDA-approved for a women's-health indication: bremelanotide, known in research circles as PT-141 and marketed as Vyleesi. The FDA approved it on June 21, 2019 to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women (FDA, 2019). It is a melanocortin-receptor agonist — the first as-needed treatment approved for this indication.

Its approval rests on two identical Phase 3 randomized, double-blind, placebo-controlled trials (the RECONNECT program). Of 1,247 premenopausal women with HSDD in the safety population, those taking bremelanotide 1.75 mg subcutaneously as-needed showed a statistically significant improvement in sexual-desire score (combined +0.35 vs. placebo, P<.001) and a reduction in associated distress (combined −0.33, P<.001) over 24 weeks (Kingsberg et al., 2019, Obstetrics & Gynecology). The magnitude of benefit is modest, and the approval is specifically for premenopausal women — not postmenopausal women or men.

Learn more in our PT-141 complete guide.

What other peptides are discussed for women, and what does the evidence show?

Beyond PT-141, the peptides most commonly discussed in women's hormonal-health circles are research compounds. None is FDA-approved for the uses below, and human data in women are sparse.

Growth-hormone-axis peptides (CJC-1295, a long-acting GHRH analog, plus the secretagogue ipamorelin) raise growth hormone and IGF-1. A single dose of CJC-1295 produced dose-dependent 2- to 10-fold increases in growth hormone and 1.5- to 3-fold increases in IGF-1 in healthy adults (Teichman et al., 2006, J Clin Endocrinol Metab). That study was not in a women's-health or menopausal population, and CJC-1295/ipamorelin remain not FDA-approved. See our CJC-1295 and ipamorelin guide.

Tesamorelin is a GHRH analog the FDA approved in 2010 (brand name Egrifta) — but only to reduce excess abdominal fat in patients with HIV-associated lipodystrophy, not for menopause or general body composition (Theratechnologies/FDA, 2010).

BPC-157 is frequently marketed for recovery and joint comfort, but a 2025 systematic review identified 35 preclinical studies and just one clinical study, concluding that no large randomized trial has established efficacy and that human safety remains unknown (Vasireddi et al., 2025, HSS Journal). Animal-model findings have not been validated in women.

How does being female change the way peptides act?

Sex is not a footnote in peptide pharmacology — it can change the result. The clearest example is the growth-hormone axis: estrogen is a proximate mediator of gender differences in GH output, and women secrete more GH per burst than men, so a woman still producing meaningful estrogen may mount a different GH response to a GH-axis peptide than a postmenopausal woman or a man (Veldhuis, 1998, Growth Horm IGF Res). Hormonal fluctuations across the cycle and into perimenopause may further modulate GH and IGF-1 production, an effect characterized for exogenous estrogen but not yet mapped for most research peptides (Southmayd & De Souza, 2017, Growth Horm IGF Res).

There is also a documented research gap: most peptide studies enroll men or mixed populations without sex-stratified analysis, so dosing parameters circulating online are rarely validated in women. This is precisely why dosing should never be self-directed. Consult your healthcare provider before starting any peptide protocol.

What are the safety considerations for women?

Safety data vary enormously between the one approved peptide and the research compounds.

For PT-141 (Vyleesi), the prescribing information is explicit. It is contraindicated in women with uncontrolled hypertension or known cardiovascular disease, because each dose transiently raises blood pressure (maximal increases of about 6 mmHg systolic and 3 mmHg diastolic, peaking 2–4 hours post-dose) and lowers heart rate, typically returning to baseline within 12 hours (Vyleesi prescribing information, FDA/DailyMed). The most common adverse event was nausea, reported in roughly 40% of treated women versus about 1% on placebo in the RECONNECT trials (Kingsberg et al., 2019). Focal hyperpigmentation — including of the face, gums, and breasts — occurred in about 1% of women receiving up to eight doses per month (Vyleesi prescribing information).

For research peptides (CJC-1295, ipamorelin, BPC-157, and similar), there is no comparable safety dossier. Human safety for BPC-157 remains formally unknown (Vasireddi et al., 2025), and GH-axis peptides carry theoretical concerns around insulin sensitivity and unmonitored IGF-1 elevation. Compounded and "research-use-only" products also raise sourcing and purity concerns. Anyone considering these should review safety with a provider who can order appropriate monitoring. Consult your healthcare provider before starting any peptide protocol.

Are peptides for women legal in 2026?

The legal picture shifted in 2026 and is still moving. In April 2026, the FDA removed 12 peptides — including BPC-157, TB-500, and MOTS-c — from Category 2 of its interim 503A compounding list, the "significant safety risk / do not compound" bucket, effective April 22, 2026 (FDA, 2026; Orrick analysis, 2026). Crucially, removal from Category 2 does not by itself authorize compounding or place a substance on the 503A bulks list.

The next step is a Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23–24, 2026, at which the committee will consider whether to recommend seven peptides — including BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon, and DSIP/emideltide — for inclusion on the 503A bulks list (FDA, 2026). A further PCAC review of additional peptides (such as GHK-Cu and Melanotan II) is anticipated before the end of February 2027.

PT-141 (Vyleesi) is unaffected by these compounding actions because it is an FDA-approved drug available by prescription. Legal status varies by jurisdiction; consult a lawyer for binding advice. See our 2026 peptide legality overview.

Frequently asked questions

Q: Are peptides safe for women? A: It depends on the peptide. PT-141 (Vyleesi) has an FDA-reviewed safety profile but is contraindicated in women with uncontrolled hypertension or cardiovascular disease and commonly causes nausea (about 40% of users in trials). Most other peptides discussed for women — including BPC-157 and GH-axis peptides — are research compounds whose human safety is not well established, particularly in female and perimenopausal populations. Consult your healthcare provider before starting any peptide protocol.

Q: Which peptide is approved for women? A: Bremelanotide, known as PT-141 and sold as Vyleesi, is the only peptide FDA-approved for a women's-health indication. It was approved in June 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, administered as a 1.75 mg subcutaneous injection as needed. It is not approved for postmenopausal women, men, or other uses.

Q: Can peptides help with menopause symptoms? A: No peptide is FDA-approved for menopause or perimenopause. PT-141's approval is specific to premenopausal women with HSDD. Peptides marketed for menopausal energy, libido, or joint comfort — such as CJC-1295/ipamorelin or BPC-157 — have not been tested in clinical trials of menopausal women, so claims of benefit are not supported by high-quality human evidence. Discuss menopause management with your healthcare provider.

Q: Do women need lower peptide doses than men? A: For growth-hormone-axis peptides, estrogen status influences the body's own GH and IGF-1 output (Veldhuis, 1998; Southmayd & De Souza, 2017), so a woman's response to a GH-axis peptide may differ from a man's, and providers often individualize starting points. However, sex-stratified dosing data are limited because most studies were not designed to compare women and men. Dosing should be personalized with a provider, never self-directed.

Q: Is PT-141 the same as Vyleesi? A: Yes. PT-141 is the research/development name for bremelanotide, and Vyleesi is the FDA-approved branded product. Both refer to the same melanocortin-receptor-agonist peptide. The approved product is a 1.75 mg single-use autoinjector for as-needed use in premenopausal women with HSDD.

Q: Are peptides for women legal right now? A: PT-141 (Vyleesi) is a legal, FDA-approved prescription drug. For research peptides, the FDA removed 12 from its Category 2 "do not compound" list in April 2026, but that did not authorize compounding; a PCAC committee reviews seven peptides on July 23–24, 2026 to decide whether they may be added to the 503A bulks list. Legal status varies by jurisdiction; consult a lawyer for binding advice.

References

1. U.S. Food and Drug Administration. FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women (Vyleesi/bremelanotide approval, June 21, 2019). https://www.prnewswire.com/news-releases/fda-approves-new-treatment-for-hypoactive-sexual-desire-disorder-in-premenopausal-women-300872998.html
2. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899–908. PMID: 31599840. https://pmc.ncbi.nlm.nih.gov/articles/PMC6819021/
3. Vyleesi (bremelanotide injection) Prescribing Information. DailyMed / U.S. FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9
4. Teichman SL, Neale A, Lawrence B, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. J Clin Endocrinol Metab. 2006;91(3):799–805. PMID: 16352683. DOI: 10.1210/jc.2005-1536. https://doi.org/10.1210/jc.2005-1536
5. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949. DOI: 10.1177/15563316251355551. https://journals.sagepub.com/doi/abs/10.1177/15563316251355551
6. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
7. Orrick, Herrington & Sutcliffe LLP. FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to 503A Bulk Drug Substances List (April 2026). https://www.orrick.com/en/Insights/2026/04/FDA-Announces-Removal-of-12-Peptides-from-Category-2-and-Schedules-PCAC-Meetings
8. Veldhuis JD. Neuroendocrine control of pulsatile growth hormone release in the human: relationship with gender. Growth Horm IGF Res. 1998;8 Suppl B:49–59. PMID: 10990135. https://pubmed.ncbi.nlm.nih.gov/10990135/
9. Southmayd EA, De Souza MJ. A summary of the influence of exogenous estrogen administration across the lifespan on the GH/IGF-1 axis and implications for bone health. Growth Horm IGF Res. 2017;32:2–13. PMID: 27693042. https://pubmed.ncbi.nlm.nih.gov/27693042/